Alzheimer disease neuropathology in a patient previously treated with aducanumab

Amyloid beta (Aβ) plaque is a defining pathologic feature of Alzheimer disease (AD). Aducanumab, a monoclonal IgG1 that selectively binds aggregated species of Aβ, has been shown by amyloid positron emission tomography (Amyloid PET) to reduce Aβ plaques in patients with prodromal and mild AD. This i...

Descripción completa

Detalles Bibliográficos
Autores principales: Plowey, Edward D., Bussiere, Thierry, Rajagovindan, Raj, Sebalusky, Jennifer, Hamann, Stefan, von Hehn, Christian, Castrillo-Viguera, Carmen, Sandrock, Alfred, Budd Haeberlein, Samantha, van Dyck, Christopher H., Huttner, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217863/
https://www.ncbi.nlm.nih.gov/pubmed/35581440
http://dx.doi.org/10.1007/s00401-022-02433-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217863/
https://www.ncbi.nlm.nih.gov/pubmed/35581440
http://dx.doi.org/10.1007/s00401-022-02433-4

Ejemplares similares